This annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma
This annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by providing a forum to:
Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.
Who Should Attend?
Save the Date:
February 3-5, 2016
Salt Lake City, Utah
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.